With 4.14 million shares changed hands, the volume of the stock remained heavier than its average volume of 1.25 million shares. During the session, the Drug Manufacturers – Specialty & Generic company that operates in wider Healthcare sector, reached to the highest price of $23.86 whereas the lowest price it dropped to was $22.62. The 52-week range on PRGO shows that it touched its highest point at $30.93 and its lowest point at $21.03 during that stretch. It currently has a 1-year price target of $34.00. With its current market cap of 3.14 billion, PRGO has annualized dividend of $1.13 while the current yield stands at 4.96%. PRGO paid its most recent dividend on 1748563200, while the ex-dividend date for that was 1756425600. Beta for the stock currently stands at 0.49.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of PRGO was down-trending over the past week, with a drop of -14.40%, but this was down by -16.13% over a month. Three-month performance dropped to -13.56% while six-month performance fell -9.04%. The stock lost -11.20% in the past year, while it has lost -20.45% so far this year. A look at the trailing 12-month EPS for PRGO yields -0.56 with Next year EPS estimates of 3.13. For the next quarter, that number is 0.76. This implies an EPS growth rate of 16.53% for this year and 4.65% for next year.
Float and Shares Shorts:
At present, 137.60 million PRGO shares are outstanding with a float of 136.82 million shares on hand for trading. On 2025-07-15, short shares totaled 6.34 million, which was 461.00000000000006 higher than short shares on 1749772800. In addition to Mr. Patrick Lockwood-Taylor as the firm’s President, CEO & Director, Mr. Eduardo Guarita Bezerra serves as its Executive VP & CFO.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2025-03-29, PRGO reported revenue of $1056300000.0 and operating income of $55600000.0. The EBITDA in the recently reported quarter was $139300000.0 and diluted EPS was -$0.06.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for PRGO since 8 analysts follow the stock currently. There are 4 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 4 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With PRGO analysts setting a high price target of 40.0 and a low target of 27.0, the average target price over the next 12 months is 34.25. Based on these targets, PRGO could surge 75.21% to reach the target high and rise by 18.27% to reach the target low. Reaching the average price target will result in a growth of 50.02% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. Analysts have provided yearly estimates in a range of $2.58002 being high and $2.53002 being low. For PRGO, this leads to a yearly average estimate of $2.56002. The surprise factor in the prior quarter was $0.57. Based on analyst estimates, the high estimate for the next quarter is $1.08 and the low estimate is $1.0. The average estimate for the next quarter is thus $1.04.
